Qu, WenchunWang, ZhenHare, Joshua MBu, GuojunMallea, Jorge MPascual, Jorge MCaplan, Arnold IKurtzberg, JoanneZubair, Abba CKubrova, EvaEngelberg-Cook, EricaNayfeh, TarekShah, Vishal PHill, James CWolf, Michael EProkop, Larry JMurad, M HassanSanfilippo, Fred P2022-03-232022-03-232020-092157-65642157-6580https://hdl.handle.net/10161/24576Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo-capillary barriers. The authors performed a systematic literature review and random-effects meta-analysis to determine the potential value of MSC therapy for treating COVID-19-infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO₂ /FiO₂ ratio, alveolo-capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.LungMesenchymal Stem CellsHumansPneumonia, ViralCoronavirus InfectionsCytokinesMesenchymal Stem Cell TransplantationPandemicsCell- and Tissue-Based TherapyBetacoronavirusRespiratory Distress SyndromeCOVID-19SARS-CoV-2Journal article2022-03-23